research institutes in two ways: one is to provide cells, and the other is to provide funds. Companies that operate the public and private combination model can provide donated stem cells to clinical trials, preclinical trials, animal studies and basic research. By comparison, providing stem cells for research is not possible with the donatable family banking model because the customers own the cells. Nevertheless, these banks sometimes sponsor research and clinical trials, which help advance the clinical application of stem cells. Compared to public banks that have restricted financial support, which constrains their research activity and collaboration, these hybrid banks can be active in collaborating with research institutes. The advances made as a result of the collaborations in turn benefit the cord blood business.
The donated cord blood units in the public and private combination model and the units in the donatable family banking model can be found in the international registries for allogeneic transplantations. These units have been tested for markers of infectious diseases. Nevertheless, in the donatable family banking model, the units need not follow the high volume or total nucleated cells set for public banks, nor complete a six-month follow-up.
Finally, as with public banks, both models charge a release fee when a unit is used for transplantation. Greater financial input is required for an organization operating a public and private combination model because it does not charge collection and storage fees for the donated cord blood. The storage of the donated cord blood is very expensive. Even so, these banks attract income from their family banking and the release fee for the donated samples. Therefore, compared with the traditional public banks, the hybrid model lowers the risk of financial crisis. With the donatable family banking model, the financial burden is light as it charges a collection fee, a storage fee and usually a release fee as well. In addition, the price that parents pay to store the cord blood in the donatable family banking model is usually higher than that in the traditional family banking model because of extra services such as HLA typing and uploading data to international registries. Yet, this model is still welcomed by parents, who recognize that the likelihood of using the cord blood within their family is very low, and appreciate the opportunity to get a refund if the cord blood is matched and used by other patients.
In conclusion, whereas traditional public and private banking are two extremes of the spectrum, hybrid banking models provide a third way 4 . Some private companies are operating the public and private combination model that sustains the cord blood donation program with private funding. In addition, the donatable family banking model provides an opportunity for the family-banked cord blood units to be searched and used by the public. In these innovative hybrid models, private cord blood companies facilitate cell flow and research collaboration, rather than just driving profit. The industry and research collaboration can promote a winwin situation for stem call science. Finally, these two hybrid models could be useful for banks to collect cord blood and increase its use in allogeneic transplantation in countries without a government-funded cord blood donation program.
The morality of patents on preimplantation genetic diagnosis
To the Editor: Laura DeFrancesco's news story in the January issue on 23andMe's 'designer baby' patent brings up challenging moral questions related to patent law 1 . The patent describes a method for predicting the phenotypes of human offspring based on genetic characteristics of embryos 2 . The method could be employed by couples who are planning to use pre-implantation genetic diagnosis (PGD)-the genetic testing of embryos created by in vitro fertilization (IVF) before implantation-to avoid the birth of a child likely to develop a genetic disease 3, 4 .
However, PGD can be used not only to prevent diseases, but also to select for desired phenotypes, such as sex or eye color. As our knowledge of the genetic basis of complex phenotypes improves, it may be possible to use PGD to select for genetic propensities for intelligence, height, athletic or musical ability, or other traits 4 . Many people have objected to using PGD for purposes other than disease prevention because this would treat children as objects that can be manipulated or exploited, not as human beings with inherent dignity or moral worth 5, 6 . Others are concerned that using PGD to design children will deny them a right to an open future by constraining their choices related to careers, interests and life plans 7 , and some have argued that widespread use of PDG will exacerbate discrimination based on race, sex and disability 8 .
US patent law requires that inventions be novel, nonobvious and useful 9 . It does not require that inventions meet moral standards, although the courts have ruled that patents cannot be awarded on inventions that fulfill no lawful purpose 10 . Whereas many people have objected to human gene patents on moral grounds 11 , the US Supreme Court did not refer to moral arguments when it ruled that patents on isolated and purified DNA sequences are invalid. The court held that these patents are invalid because isolated and purified DNA sequences found in nature have not been changed enough to qualify as human inventions. Naturally occurring DNA sequences that have been modified by human beings in some way, such as complementary DNA (cDNA), can be patented 12 .
The situation in Europe is very different. Nations that belong to the European Union (EU) are bound to follow the European Directive on the Legal Protection of Biotechnological Inventions, adopted by the European Parliament in 1998, which prohibits patenting inventions that offend the ordre public (or public morality) 13 . Some examples of inventions that offend the public morality, according to the Directive, include processes for modifying the human germline or cloning
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human beings and inventions that use human embryos for commercial purposes. The Directive does not explicitly prohibit patents on PGD methods 13 .
Because US patent law does not require that inventions satisfy a morality condition, it is unlikely the courts will invalidate 23andMe's (Mountain View, CA, USA) patent on moral grounds. It remains to be seen how European courts will deal with patents on PGD processes. The debate about the patentability of human embryonic stem (hES) cells could foreshadow how European countries and the United States will address these issues. Although the United States continues to recognize patents on hES cells as valid, the European Court of Justice, which has jurisdiction over members of the EU, has ruled that inventions involving the destruction of human embryos cannot be patented because they offend public morality. Stem cell lines created by methods that do not involve the destruction of embryos might be patentable, however 14 . It is conceivable that the EU could declare PGD patents invalid on moral grounds.
In thinking about the moral and policy issues related to 23andMe's patent, it is important to appreciate three pertinent facts. First, PGD occurred long before the patent was issued and will continue to occur regardless of whether any methods of testing and selecting embryos are patented. Rejecting PGD patents on moral grounds is not likely to stop 23andMe or other companies from developing this reproductive technology.
Second, PGD is legal in the United States and many other countries. Some countries, including Australia, the UK and Germany, regulate PGD. The UK's Human Fertilisation and Embryology Authority (London) licenses fertility specialists to perform PGD for 280 genetic conditions 15 .
Third, the process patented by 23andMe can be used for a good purpose (i.e., to predict disease susceptibility). Many patented inventions have good and bad uses. Rejecting a patent because an invention could be used for bad or ethically questionable purposes is like throwing the baby out with the bath water. Some couples that learn the sex of their child through ultrasound imaging decide to abort children of an unwanted sex 16 . Although selective abortion based on sex is ethically questionable because it is a form of sexual discrimination that skews the sex ratio, it would be imprudent to refuse to grant patents for sonogram machines on the grounds that they could be used to inform decisions leading to selective abortion based on sex. The wisest course of action is to grant these patents but take steps to regulate the practice of selective abortion to avoid sexual discrimination. Likewise, in the case of 23andMe's invented process, the most reasonable policy is to grant the patent but take steps to regulate PGD to avoid designer babies and other ethical problems related to this technology.
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Putting cells to sleep for future science
To the Editor: Central to the delivery of biotechnological and biomedical products is the ability to preserve and store biological reagents and materials with guaranteed genetic and phenotypic stability. This is vital to secure starting materials, reproducibility of manufacturing processes, consistency of the result or product and requirements for patent deposits. Although freeze-drying (lyophilization) may be used to stabilize some biological materials, including many strains of bacteria and fungi, it cannot guarantee indefinite viability and maintenance of sample quality. Cryopreservation (preservation in an aqueous state) is widely assumed to provide the answer to the question of how best to maintain master stocks of cell lines and other biological materials, but this is often a matter of faith rather than the application of qualified technology. Here we explore the current state of the 'art' , with an emphasis on where research and training is urgently needed to ensure the necessary skills are maintained and to assure the applicability, efficacy and sustainability of this important technology.
Storage at ultra-low temperatures effectively places cells in suspended animation. Assuming the thermal stability of the system used to store the cells is maintained below a critical temperature (that is, glass-transition temperature that is typically around -130 °C), the 'shelf-life' of stored specimens may be theoretically decades, if not hundreds of years. However, the approaches used to develop cryopreservation protocols are typically empirical and do not match the sophistication of current '-omics' analytical systems, for example. These new technologies offer the prospect of bringing an unprecedented level of scientific scrutiny to sample characterization and integrity before and after storage.
In addition, parameters for preservation methods, critical storage temperature and recovery vary with the cell type, the medium in which they are preserved and the preservation technique used. There is rarely any substantial degree of assurance that material recovered, as live cultures in the future, will have conserved the properties of the original cells. Furthermore-contrary to common scientific belief-many taxa and cell lines with biotechnological potential are recalcitrant to current cryopreservation procedures and either do not survive, have unacceptably low levels of survival or may lose critical characteristics that are difficult to measure. Developing new biotechnological
